Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates
Background: Hemophilia A (HA) is a hereditary X-linked hemorrhagic disorder. Following the first treatment with exogenous factor (F)VIII, one-third of patients with severe HA develop anti-FVIII antibodies (inhibitors), which render treatment ineffective. Recent findings underlined the critical role...
Saved in:
Similar Items
-
Hypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic Review.
by: Alberto Maino, et al.
Published: (2015-01-01) -
Challenges and considerations of genetic testing in von Willebrand disease
by: Omid Seidizadeh, et al.
Published: (2025-01-01) -
Synovial Gene expression after Hemarthrosis differs between FVIII-deficient mice treated with recombinant FVIII or FVIII-Fc Fusion Protein
by: Bilgimol Chumappumkal Joseph, et al.
Published: (2025-01-01) -
Impact of blood centrifugation on the parameters of thrombin generation assay revisited to look for possible revision of the current guidance
by: Erica Scalambrino, et al.
Published: (2025-07-01) -
Patient anti-FVIII drug antibodies bind preferentially to a subset of FVIII covalent states
by: Diego Butera, et al.
Published: (2025-08-01)